Drug manufacturers are root cause of high drug costs; PBMs drive costs down

The Hill

30 June 2022 - It should come as no surprise that pharmacy benefit managers applaud Congress for recent bipartisan action to further delay the rebate rule as part of legislation to address gun safety and mental health. 

In the long running debate on lowering prescription drug costs, the rebate rule is the poster child for the counterfactual on how to achieve that objective.

Read The Hill article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Pricing , Pharmacy